Global Childhood Vaccines

Childhood Vaccines Comprehensive Study by Type (Monovalent Vaccines, Multivalent Vaccines), Route of Administration (Intramuscular and Subcutaneous Administration, Oral Administration, Others), Technology (Conjugate Vaccines, Inactivated and Subunit Vaccines, Live Attenuated Vaccines, Recombinant Vaccines, Toxoid Vaccines), Disease Indications (Pneumococcal disease, DTP, Influenza, HPV, Meningococcal disease, Polio, Rotavirus, Hepatitis, MMR, Varicella, Herpes zoster, Others) Players and Region - Global Market Outlook to 2030

Childhood Vaccines Market by XX Submarkets | Forecast Years 2024-2030  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
About Childhood Vaccines
The childhood vaccine is a practice of killed microorganisms, dwelling attenuated organisms, or dwelling utterly virulent organisms that are administered to stimulate the manufacturing of antibodies and grant immunity in opposition to one or quite a few illnesses amongst children. Childhood vaccines are used in childhood immunization schedules to decorate a kid's immunity or stop ailments such as diphtheria, tetanus, pertussis, influenza, Hepatitis B, polio, and many different infectious and non-infectious diseases.

AttributesDetails
Study Period2018-2030
Base Year2023
UnitValue (USD Million)


The market is seeing moderate market players, by seeing huge growth in this market the key leading vendors are highly focusing towards the production technologies, efficiency enhancement and product life. There is various growth opportunity in this market which is captured by leading players via tracking the ongoing process enhancement and huge invest in market growth strategies. Analyst at AMA Research estimates that United States Players will contribute the maximum growth to Global Childhood Vaccines market throughout the forecasted period. Established and emerging Players should take a closer view at their existing organizations and reinvent traditional business and operating models to adapt to the future.

GlaxoSmithKline plc. (United Kingdom), Pfizer, Inc. (United States), Merck & Co., Inc. (United States), Sanofi Pasteur SA (France), CSL Limited (Australia), Emergent Bio Solutions, Inc. (United States), Johnson & Johnson (United States), Serum Institute of India (India), AstraZeneca (United Kingdom) and Bavarian Nordic (Denmark) are some of the key players that are part of study coverage. Additionally, the Players which are also part of the research coverage are Mitsubishi Tanabe Pharma Corporation (Japan) and Daiichi Sankyo Company, Limited (Japan).

Segmentation Overview
AMA Research has segmented the market of Global Childhood Vaccines market by Type (Monovalent Vaccines and Multivalent Vaccines) and Region.



On the basis of geography, the market of Childhood Vaccines has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). If we see Market by Route of Administration, the sub-segment i.e. Intramuscular and Subcutaneous Administration will boost the Childhood Vaccines market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by Technology, the sub-segment i.e. Conjugate Vaccines will boost the Childhood Vaccines market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by Disease Indications, the sub-segment i.e. Pneumococcal disease will boost the Childhood Vaccines market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.

Influencing Trend:
Increasing Company Initiatives to Enhance Vaccine R&D

Market Growth Drivers:
High Prevalence of Infectious Diseases

Challenges:
Demand for Novel Vaccines is Steadily Growing to Deliver Improved Immunization against Infectious Diseases

Restraints:
Huge Capital Investments

Opportunities:
High Growth Prospects in Emerging Markets

Market Leaders and their expansionary development strategies
In January 2020, Hilleman laboratories, global research, and development organization, has announced their plans to develop a novel vaccine against Group B Streptococcus, a major cause for neonatal infections in women, in the area of maternal and child health.
In June 2022, Gavi, the Vaccine Alliance launched the Zero-Dose Immunization Programme (ZIP), a new innovative initiative that has provide two consortia of partners with up to USD 100 million to identify and reach zero-dose children living in displaced communities and fragile and conflict settings. Zero-dose children are those that have not received a single shot of a routine vaccine.
The U.S. Food and Drug Administration’s (FDA’s) Center for Biologics Evaluation and Research External (CBER) is responsible for regulating vaccines in the United States. The sponsor of a new vaccine product follows a multi-step approval process which are "An Investigational New Drug application, Pre-licensure vaccine clinical trials, A Biologics License Application (BLA), Inspection of the manufacturing facility, Presentation of findings to FDA’s Vaccines and Related Biological Products Advisory Committee External (VRBPAC) and Usability testing of product labeling.

Key Target Audience
Childhood Vaccines Manufacturers, Childhood Vaccines distributors and Suppliers, Venture Capitalists and Private Equity Firms, Government Bodies, Corporate Entities, Government and Private Research Organizations and Others

About Approach
To evaluate and validate the market size various sources including primary and secondary analysis is utilized. AMA Research follows regulatory standards such as NAICS/SIC/ICB/TRCB, to have a better understanding of the market. The market study is conducted on basis of more than 200 companies dealing in the market regional as well as global areas with the purpose to understand the companies positioning regarding the market value, volume, and their market share for regional as well as global.

Further to bring relevance specific to any niche market we set and apply a number of criteria like Geographic Footprints, Regional Segments of Revenue, Operational Centres, etc. The next step is to finalize a team (In-House + Data Agencies) who then starts collecting C & D level executives and profiles, Industry experts, Opinion leaders, etc., and work towards appointment generation.

The primary research is performed by taking the interviews of executives of various companies dealing in the market as well as using the survey reports, research institute, and latest research reports. Meanwhile, the analyst team keeps preparing a set of questionnaires, and after getting the appointee list; the target audience is then tapped and segregated with various mediums and channels that are feasible for making connections that including email communication, telephonic, skype, LinkedIn Group & InMail, Community Forums, Community Forums, open Survey, SurveyMonkey, etc.

Report Objectives / Segmentation Covered

By Type
  • Monovalent Vaccines
  • Multivalent Vaccines
By Route of Administration
  • Intramuscular and Subcutaneous Administration
  • Oral Administration
  • Others

By Technology
  • Conjugate Vaccines
  • Inactivated and Subunit Vaccines
  • Live Attenuated Vaccines
  • Recombinant Vaccines
  • Toxoid Vaccines

By Disease Indications
  • Pneumococcal disease
  • DTP
  • Influenza
  • HPV
  • Meningococcal disease
  • Polio
  • Rotavirus
  • Hepatitis
  • MMR
  • Varicella
  • Herpes zoster
  • Others

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. High Prevalence of Infectious Diseases
    • 3.3. Market Challenges
      • 3.3.1. Demand for Novel Vaccines is Steadily Growing to Deliver Improved Immunization against Infectious Diseases
    • 3.4. Market Trends
      • 3.4.1. Increasing Company Initiatives to Enhance Vaccine R&D
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Childhood Vaccines, by Type, Route of Administration, Technology, Disease Indications and Region (value) (2018-2023)
    • 5.1. Introduction
    • 5.2. Global Childhood Vaccines (Value)
      • 5.2.1. Global Childhood Vaccines by: Type (Value)
        • 5.2.1.1. Monovalent Vaccines
        • 5.2.1.2. Multivalent Vaccines
      • 5.2.2. Global Childhood Vaccines by: Route of Administration (Value)
        • 5.2.2.1. Intramuscular and Subcutaneous Administration
        • 5.2.2.2. Oral Administration
        • 5.2.2.3. Others
      • 5.2.3. Global Childhood Vaccines by: Technology (Value)
        • 5.2.3.1. Conjugate Vaccines
        • 5.2.3.2. Inactivated and Subunit Vaccines
        • 5.2.3.3. Live Attenuated Vaccines
        • 5.2.3.4. Recombinant Vaccines
        • 5.2.3.5. Toxoid Vaccines
      • 5.2.4. Global Childhood Vaccines by: Disease Indications (Value)
        • 5.2.4.1. Pneumococcal disease
        • 5.2.4.2. DTP
        • 5.2.4.3. Influenza
        • 5.2.4.4. HPV
        • 5.2.4.5. Meningococcal disease
        • 5.2.4.6. Polio
        • 5.2.4.7. Rotavirus
        • 5.2.4.8. Hepatitis
        • 5.2.4.9. MMR
        • 5.2.4.10. Varicella
        • 5.2.4.11. Herpes zoster
        • 5.2.4.12. Others
      • 5.2.5. Global Childhood Vaccines Region
        • 5.2.5.1. South America
          • 5.2.5.1.1. Brazil
          • 5.2.5.1.2. Argentina
          • 5.2.5.1.3. Rest of South America
        • 5.2.5.2. Asia Pacific
          • 5.2.5.2.1. China
          • 5.2.5.2.2. Japan
          • 5.2.5.2.3. India
          • 5.2.5.2.4. South Korea
          • 5.2.5.2.5. Taiwan
          • 5.2.5.2.6. Australia
          • 5.2.5.2.7. Rest of Asia-Pacific
        • 5.2.5.3. Europe
          • 5.2.5.3.1. Germany
          • 5.2.5.3.2. France
          • 5.2.5.3.3. Italy
          • 5.2.5.3.4. United Kingdom
          • 5.2.5.3.5. Netherlands
          • 5.2.5.3.6. Rest of Europe
        • 5.2.5.4. MEA
          • 5.2.5.4.1. Middle East
          • 5.2.5.4.2. Africa
        • 5.2.5.5. North America
          • 5.2.5.5.1. United States
          • 5.2.5.5.2. Canada
          • 5.2.5.5.3. Mexico
  • 6. Childhood Vaccines: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2023)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. GlaxoSmithKline plc. (United Kingdom)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Pfizer, Inc. (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Merck & Co., Inc. (United States)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Sanofi Pasteur SA (France)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. CSL Limited (Australia)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Emergent Bio Solutions, Inc. (United States)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Johnson & Johnson (United States)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Serum Institute of India (India)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. AstraZeneca (United Kingdom)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Bavarian Nordic (Denmark)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global Childhood Vaccines Sale, by Type, Route of Administration, Technology, Disease Indications and Region (value) (2025-2030)
    • 7.1. Introduction
    • 7.2. Global Childhood Vaccines (Value)
      • 7.2.1. Global Childhood Vaccines by: Type (Value)
        • 7.2.1.1. Monovalent Vaccines
        • 7.2.1.2. Multivalent Vaccines
      • 7.2.2. Global Childhood Vaccines by: Route of Administration (Value)
        • 7.2.2.1. Intramuscular and Subcutaneous Administration
        • 7.2.2.2. Oral Administration
        • 7.2.2.3. Others
      • 7.2.3. Global Childhood Vaccines by: Technology (Value)
        • 7.2.3.1. Conjugate Vaccines
        • 7.2.3.2. Inactivated and Subunit Vaccines
        • 7.2.3.3. Live Attenuated Vaccines
        • 7.2.3.4. Recombinant Vaccines
        • 7.2.3.5. Toxoid Vaccines
      • 7.2.4. Global Childhood Vaccines by: Disease Indications (Value)
        • 7.2.4.1. Pneumococcal disease
        • 7.2.4.2. DTP
        • 7.2.4.3. Influenza
        • 7.2.4.4. HPV
        • 7.2.4.5. Meningococcal disease
        • 7.2.4.6. Polio
        • 7.2.4.7. Rotavirus
        • 7.2.4.8. Hepatitis
        • 7.2.4.9. MMR
        • 7.2.4.10. Varicella
        • 7.2.4.11. Herpes zoster
        • 7.2.4.12. Others
      • 7.2.5. Global Childhood Vaccines Region
        • 7.2.5.1. South America
          • 7.2.5.1.1. Brazil
          • 7.2.5.1.2. Argentina
          • 7.2.5.1.3. Rest of South America
        • 7.2.5.2. Asia Pacific
          • 7.2.5.2.1. China
          • 7.2.5.2.2. Japan
          • 7.2.5.2.3. India
          • 7.2.5.2.4. South Korea
          • 7.2.5.2.5. Taiwan
          • 7.2.5.2.6. Australia
          • 7.2.5.2.7. Rest of Asia-Pacific
        • 7.2.5.3. Europe
          • 7.2.5.3.1. Germany
          • 7.2.5.3.2. France
          • 7.2.5.3.3. Italy
          • 7.2.5.3.4. United Kingdom
          • 7.2.5.3.5. Netherlands
          • 7.2.5.3.6. Rest of Europe
        • 7.2.5.4. MEA
          • 7.2.5.4.1. Middle East
          • 7.2.5.4.2. Africa
        • 7.2.5.5. North America
          • 7.2.5.5.1. United States
          • 7.2.5.5.2. Canada
          • 7.2.5.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Childhood Vaccines: by Type(USD Million)
  • Table 2. Childhood Vaccines Monovalent Vaccines , by Region USD Million (2018-2023)
  • Table 3. Childhood Vaccines Multivalent Vaccines , by Region USD Million (2018-2023)
  • Table 4. Childhood Vaccines: by Route of Administration(USD Million)
  • Table 5. Childhood Vaccines Intramuscular and Subcutaneous Administration , by Region USD Million (2018-2023)
  • Table 6. Childhood Vaccines Oral Administration , by Region USD Million (2018-2023)
  • Table 7. Childhood Vaccines Others , by Region USD Million (2018-2023)
  • Table 8. Childhood Vaccines: by Technology(USD Million)
  • Table 9. Childhood Vaccines Conjugate Vaccines , by Region USD Million (2018-2023)
  • Table 10. Childhood Vaccines Inactivated and Subunit Vaccines , by Region USD Million (2018-2023)
  • Table 11. Childhood Vaccines Live Attenuated Vaccines , by Region USD Million (2018-2023)
  • Table 12. Childhood Vaccines Recombinant Vaccines , by Region USD Million (2018-2023)
  • Table 13. Childhood Vaccines Toxoid Vaccines , by Region USD Million (2018-2023)
  • Table 14. Childhood Vaccines: by Disease Indications(USD Million)
  • Table 15. Childhood Vaccines Pneumococcal disease , by Region USD Million (2018-2023)
  • Table 16. Childhood Vaccines DTP , by Region USD Million (2018-2023)
  • Table 17. Childhood Vaccines Influenza , by Region USD Million (2018-2023)
  • Table 18. Childhood Vaccines HPV , by Region USD Million (2018-2023)
  • Table 19. Childhood Vaccines Meningococcal disease , by Region USD Million (2018-2023)
  • Table 20. Childhood Vaccines Polio , by Region USD Million (2018-2023)
  • Table 21. Childhood Vaccines Rotavirus , by Region USD Million (2018-2023)
  • Table 22. Childhood Vaccines Hepatitis , by Region USD Million (2018-2023)
  • Table 23. Childhood Vaccines MMR , by Region USD Million (2018-2023)
  • Table 24. Childhood Vaccines Varicella , by Region USD Million (2018-2023)
  • Table 25. Childhood Vaccines Herpes zoster , by Region USD Million (2018-2023)
  • Table 26. Childhood Vaccines Others , by Region USD Million (2018-2023)
  • Table 27. South America Childhood Vaccines, by Country USD Million (2018-2023)
  • Table 28. South America Childhood Vaccines, by Type USD Million (2018-2023)
  • Table 29. South America Childhood Vaccines, by Route of Administration USD Million (2018-2023)
  • Table 30. South America Childhood Vaccines, by Technology USD Million (2018-2023)
  • Table 31. South America Childhood Vaccines, by Disease Indications USD Million (2018-2023)
  • Table 32. Brazil Childhood Vaccines, by Type USD Million (2018-2023)
  • Table 33. Brazil Childhood Vaccines, by Route of Administration USD Million (2018-2023)
  • Table 34. Brazil Childhood Vaccines, by Technology USD Million (2018-2023)
  • Table 35. Brazil Childhood Vaccines, by Disease Indications USD Million (2018-2023)
  • Table 36. Argentina Childhood Vaccines, by Type USD Million (2018-2023)
  • Table 37. Argentina Childhood Vaccines, by Route of Administration USD Million (2018-2023)
  • Table 38. Argentina Childhood Vaccines, by Technology USD Million (2018-2023)
  • Table 39. Argentina Childhood Vaccines, by Disease Indications USD Million (2018-2023)
  • Table 40. Rest of South America Childhood Vaccines, by Type USD Million (2018-2023)
  • Table 41. Rest of South America Childhood Vaccines, by Route of Administration USD Million (2018-2023)
  • Table 42. Rest of South America Childhood Vaccines, by Technology USD Million (2018-2023)
  • Table 43. Rest of South America Childhood Vaccines, by Disease Indications USD Million (2018-2023)
  • Table 44. Asia Pacific Childhood Vaccines, by Country USD Million (2018-2023)
  • Table 45. Asia Pacific Childhood Vaccines, by Type USD Million (2018-2023)
  • Table 46. Asia Pacific Childhood Vaccines, by Route of Administration USD Million (2018-2023)
  • Table 47. Asia Pacific Childhood Vaccines, by Technology USD Million (2018-2023)
  • Table 48. Asia Pacific Childhood Vaccines, by Disease Indications USD Million (2018-2023)
  • Table 49. China Childhood Vaccines, by Type USD Million (2018-2023)
  • Table 50. China Childhood Vaccines, by Route of Administration USD Million (2018-2023)
  • Table 51. China Childhood Vaccines, by Technology USD Million (2018-2023)
  • Table 52. China Childhood Vaccines, by Disease Indications USD Million (2018-2023)
  • Table 53. Japan Childhood Vaccines, by Type USD Million (2018-2023)
  • Table 54. Japan Childhood Vaccines, by Route of Administration USD Million (2018-2023)
  • Table 55. Japan Childhood Vaccines, by Technology USD Million (2018-2023)
  • Table 56. Japan Childhood Vaccines, by Disease Indications USD Million (2018-2023)
  • Table 57. India Childhood Vaccines, by Type USD Million (2018-2023)
  • Table 58. India Childhood Vaccines, by Route of Administration USD Million (2018-2023)
  • Table 59. India Childhood Vaccines, by Technology USD Million (2018-2023)
  • Table 60. India Childhood Vaccines, by Disease Indications USD Million (2018-2023)
  • Table 61. South Korea Childhood Vaccines, by Type USD Million (2018-2023)
  • Table 62. South Korea Childhood Vaccines, by Route of Administration USD Million (2018-2023)
  • Table 63. South Korea Childhood Vaccines, by Technology USD Million (2018-2023)
  • Table 64. South Korea Childhood Vaccines, by Disease Indications USD Million (2018-2023)
  • Table 65. Taiwan Childhood Vaccines, by Type USD Million (2018-2023)
  • Table 66. Taiwan Childhood Vaccines, by Route of Administration USD Million (2018-2023)
  • Table 67. Taiwan Childhood Vaccines, by Technology USD Million (2018-2023)
  • Table 68. Taiwan Childhood Vaccines, by Disease Indications USD Million (2018-2023)
  • Table 69. Australia Childhood Vaccines, by Type USD Million (2018-2023)
  • Table 70. Australia Childhood Vaccines, by Route of Administration USD Million (2018-2023)
  • Table 71. Australia Childhood Vaccines, by Technology USD Million (2018-2023)
  • Table 72. Australia Childhood Vaccines, by Disease Indications USD Million (2018-2023)
  • Table 73. Rest of Asia-Pacific Childhood Vaccines, by Type USD Million (2018-2023)
  • Table 74. Rest of Asia-Pacific Childhood Vaccines, by Route of Administration USD Million (2018-2023)
  • Table 75. Rest of Asia-Pacific Childhood Vaccines, by Technology USD Million (2018-2023)
  • Table 76. Rest of Asia-Pacific Childhood Vaccines, by Disease Indications USD Million (2018-2023)
  • Table 77. Europe Childhood Vaccines, by Country USD Million (2018-2023)
  • Table 78. Europe Childhood Vaccines, by Type USD Million (2018-2023)
  • Table 79. Europe Childhood Vaccines, by Route of Administration USD Million (2018-2023)
  • Table 80. Europe Childhood Vaccines, by Technology USD Million (2018-2023)
  • Table 81. Europe Childhood Vaccines, by Disease Indications USD Million (2018-2023)
  • Table 82. Germany Childhood Vaccines, by Type USD Million (2018-2023)
  • Table 83. Germany Childhood Vaccines, by Route of Administration USD Million (2018-2023)
  • Table 84. Germany Childhood Vaccines, by Technology USD Million (2018-2023)
  • Table 85. Germany Childhood Vaccines, by Disease Indications USD Million (2018-2023)
  • Table 86. France Childhood Vaccines, by Type USD Million (2018-2023)
  • Table 87. France Childhood Vaccines, by Route of Administration USD Million (2018-2023)
  • Table 88. France Childhood Vaccines, by Technology USD Million (2018-2023)
  • Table 89. France Childhood Vaccines, by Disease Indications USD Million (2018-2023)
  • Table 90. Italy Childhood Vaccines, by Type USD Million (2018-2023)
  • Table 91. Italy Childhood Vaccines, by Route of Administration USD Million (2018-2023)
  • Table 92. Italy Childhood Vaccines, by Technology USD Million (2018-2023)
  • Table 93. Italy Childhood Vaccines, by Disease Indications USD Million (2018-2023)
  • Table 94. United Kingdom Childhood Vaccines, by Type USD Million (2018-2023)
  • Table 95. United Kingdom Childhood Vaccines, by Route of Administration USD Million (2018-2023)
  • Table 96. United Kingdom Childhood Vaccines, by Technology USD Million (2018-2023)
  • Table 97. United Kingdom Childhood Vaccines, by Disease Indications USD Million (2018-2023)
  • Table 98. Netherlands Childhood Vaccines, by Type USD Million (2018-2023)
  • Table 99. Netherlands Childhood Vaccines, by Route of Administration USD Million (2018-2023)
  • Table 100. Netherlands Childhood Vaccines, by Technology USD Million (2018-2023)
  • Table 101. Netherlands Childhood Vaccines, by Disease Indications USD Million (2018-2023)
  • Table 102. Rest of Europe Childhood Vaccines, by Type USD Million (2018-2023)
  • Table 103. Rest of Europe Childhood Vaccines, by Route of Administration USD Million (2018-2023)
  • Table 104. Rest of Europe Childhood Vaccines, by Technology USD Million (2018-2023)
  • Table 105. Rest of Europe Childhood Vaccines, by Disease Indications USD Million (2018-2023)
  • Table 106. MEA Childhood Vaccines, by Country USD Million (2018-2023)
  • Table 107. MEA Childhood Vaccines, by Type USD Million (2018-2023)
  • Table 108. MEA Childhood Vaccines, by Route of Administration USD Million (2018-2023)
  • Table 109. MEA Childhood Vaccines, by Technology USD Million (2018-2023)
  • Table 110. MEA Childhood Vaccines, by Disease Indications USD Million (2018-2023)
  • Table 111. Middle East Childhood Vaccines, by Type USD Million (2018-2023)
  • Table 112. Middle East Childhood Vaccines, by Route of Administration USD Million (2018-2023)
  • Table 113. Middle East Childhood Vaccines, by Technology USD Million (2018-2023)
  • Table 114. Middle East Childhood Vaccines, by Disease Indications USD Million (2018-2023)
  • Table 115. Africa Childhood Vaccines, by Type USD Million (2018-2023)
  • Table 116. Africa Childhood Vaccines, by Route of Administration USD Million (2018-2023)
  • Table 117. Africa Childhood Vaccines, by Technology USD Million (2018-2023)
  • Table 118. Africa Childhood Vaccines, by Disease Indications USD Million (2018-2023)
  • Table 119. North America Childhood Vaccines, by Country USD Million (2018-2023)
  • Table 120. North America Childhood Vaccines, by Type USD Million (2018-2023)
  • Table 121. North America Childhood Vaccines, by Route of Administration USD Million (2018-2023)
  • Table 122. North America Childhood Vaccines, by Technology USD Million (2018-2023)
  • Table 123. North America Childhood Vaccines, by Disease Indications USD Million (2018-2023)
  • Table 124. United States Childhood Vaccines, by Type USD Million (2018-2023)
  • Table 125. United States Childhood Vaccines, by Route of Administration USD Million (2018-2023)
  • Table 126. United States Childhood Vaccines, by Technology USD Million (2018-2023)
  • Table 127. United States Childhood Vaccines, by Disease Indications USD Million (2018-2023)
  • Table 128. Canada Childhood Vaccines, by Type USD Million (2018-2023)
  • Table 129. Canada Childhood Vaccines, by Route of Administration USD Million (2018-2023)
  • Table 130. Canada Childhood Vaccines, by Technology USD Million (2018-2023)
  • Table 131. Canada Childhood Vaccines, by Disease Indications USD Million (2018-2023)
  • Table 132. Mexico Childhood Vaccines, by Type USD Million (2018-2023)
  • Table 133. Mexico Childhood Vaccines, by Route of Administration USD Million (2018-2023)
  • Table 134. Mexico Childhood Vaccines, by Technology USD Million (2018-2023)
  • Table 135. Mexico Childhood Vaccines, by Disease Indications USD Million (2018-2023)
  • Table 136. Company Basic Information, Sales Area and Its Competitors
  • Table 137. Company Basic Information, Sales Area and Its Competitors
  • Table 138. Company Basic Information, Sales Area and Its Competitors
  • Table 139. Company Basic Information, Sales Area and Its Competitors
  • Table 140. Company Basic Information, Sales Area and Its Competitors
  • Table 141. Company Basic Information, Sales Area and Its Competitors
  • Table 142. Company Basic Information, Sales Area and Its Competitors
  • Table 143. Company Basic Information, Sales Area and Its Competitors
  • Table 144. Company Basic Information, Sales Area and Its Competitors
  • Table 145. Company Basic Information, Sales Area and Its Competitors
  • Table 146. Childhood Vaccines: by Type(USD Million)
  • Table 147. Childhood Vaccines Monovalent Vaccines , by Region USD Million (2025-2030)
  • Table 148. Childhood Vaccines Multivalent Vaccines , by Region USD Million (2025-2030)
  • Table 149. Childhood Vaccines: by Route of Administration(USD Million)
  • Table 150. Childhood Vaccines Intramuscular and Subcutaneous Administration , by Region USD Million (2025-2030)
  • Table 151. Childhood Vaccines Oral Administration , by Region USD Million (2025-2030)
  • Table 152. Childhood Vaccines Others , by Region USD Million (2025-2030)
  • Table 153. Childhood Vaccines: by Technology(USD Million)
  • Table 154. Childhood Vaccines Conjugate Vaccines , by Region USD Million (2025-2030)
  • Table 155. Childhood Vaccines Inactivated and Subunit Vaccines , by Region USD Million (2025-2030)
  • Table 156. Childhood Vaccines Live Attenuated Vaccines , by Region USD Million (2025-2030)
  • Table 157. Childhood Vaccines Recombinant Vaccines , by Region USD Million (2025-2030)
  • Table 158. Childhood Vaccines Toxoid Vaccines , by Region USD Million (2025-2030)
  • Table 159. Childhood Vaccines: by Disease Indications(USD Million)
  • Table 160. Childhood Vaccines Pneumococcal disease , by Region USD Million (2025-2030)
  • Table 161. Childhood Vaccines DTP , by Region USD Million (2025-2030)
  • Table 162. Childhood Vaccines Influenza , by Region USD Million (2025-2030)
  • Table 163. Childhood Vaccines HPV , by Region USD Million (2025-2030)
  • Table 164. Childhood Vaccines Meningococcal disease , by Region USD Million (2025-2030)
  • Table 165. Childhood Vaccines Polio , by Region USD Million (2025-2030)
  • Table 166. Childhood Vaccines Rotavirus , by Region USD Million (2025-2030)
  • Table 167. Childhood Vaccines Hepatitis , by Region USD Million (2025-2030)
  • Table 168. Childhood Vaccines MMR , by Region USD Million (2025-2030)
  • Table 169. Childhood Vaccines Varicella , by Region USD Million (2025-2030)
  • Table 170. Childhood Vaccines Herpes zoster , by Region USD Million (2025-2030)
  • Table 171. Childhood Vaccines Others , by Region USD Million (2025-2030)
  • Table 172. South America Childhood Vaccines, by Country USD Million (2025-2030)
  • Table 173. South America Childhood Vaccines, by Type USD Million (2025-2030)
  • Table 174. South America Childhood Vaccines, by Route of Administration USD Million (2025-2030)
  • Table 175. South America Childhood Vaccines, by Technology USD Million (2025-2030)
  • Table 176. South America Childhood Vaccines, by Disease Indications USD Million (2025-2030)
  • Table 177. Brazil Childhood Vaccines, by Type USD Million (2025-2030)
  • Table 178. Brazil Childhood Vaccines, by Route of Administration USD Million (2025-2030)
  • Table 179. Brazil Childhood Vaccines, by Technology USD Million (2025-2030)
  • Table 180. Brazil Childhood Vaccines, by Disease Indications USD Million (2025-2030)
  • Table 181. Argentina Childhood Vaccines, by Type USD Million (2025-2030)
  • Table 182. Argentina Childhood Vaccines, by Route of Administration USD Million (2025-2030)
  • Table 183. Argentina Childhood Vaccines, by Technology USD Million (2025-2030)
  • Table 184. Argentina Childhood Vaccines, by Disease Indications USD Million (2025-2030)
  • Table 185. Rest of South America Childhood Vaccines, by Type USD Million (2025-2030)
  • Table 186. Rest of South America Childhood Vaccines, by Route of Administration USD Million (2025-2030)
  • Table 187. Rest of South America Childhood Vaccines, by Technology USD Million (2025-2030)
  • Table 188. Rest of South America Childhood Vaccines, by Disease Indications USD Million (2025-2030)
  • Table 189. Asia Pacific Childhood Vaccines, by Country USD Million (2025-2030)
  • Table 190. Asia Pacific Childhood Vaccines, by Type USD Million (2025-2030)
  • Table 191. Asia Pacific Childhood Vaccines, by Route of Administration USD Million (2025-2030)
  • Table 192. Asia Pacific Childhood Vaccines, by Technology USD Million (2025-2030)
  • Table 193. Asia Pacific Childhood Vaccines, by Disease Indications USD Million (2025-2030)
  • Table 194. China Childhood Vaccines, by Type USD Million (2025-2030)
  • Table 195. China Childhood Vaccines, by Route of Administration USD Million (2025-2030)
  • Table 196. China Childhood Vaccines, by Technology USD Million (2025-2030)
  • Table 197. China Childhood Vaccines, by Disease Indications USD Million (2025-2030)
  • Table 198. Japan Childhood Vaccines, by Type USD Million (2025-2030)
  • Table 199. Japan Childhood Vaccines, by Route of Administration USD Million (2025-2030)
  • Table 200. Japan Childhood Vaccines, by Technology USD Million (2025-2030)
  • Table 201. Japan Childhood Vaccines, by Disease Indications USD Million (2025-2030)
  • Table 202. India Childhood Vaccines, by Type USD Million (2025-2030)
  • Table 203. India Childhood Vaccines, by Route of Administration USD Million (2025-2030)
  • Table 204. India Childhood Vaccines, by Technology USD Million (2025-2030)
  • Table 205. India Childhood Vaccines, by Disease Indications USD Million (2025-2030)
  • Table 206. South Korea Childhood Vaccines, by Type USD Million (2025-2030)
  • Table 207. South Korea Childhood Vaccines, by Route of Administration USD Million (2025-2030)
  • Table 208. South Korea Childhood Vaccines, by Technology USD Million (2025-2030)
  • Table 209. South Korea Childhood Vaccines, by Disease Indications USD Million (2025-2030)
  • Table 210. Taiwan Childhood Vaccines, by Type USD Million (2025-2030)
  • Table 211. Taiwan Childhood Vaccines, by Route of Administration USD Million (2025-2030)
  • Table 212. Taiwan Childhood Vaccines, by Technology USD Million (2025-2030)
  • Table 213. Taiwan Childhood Vaccines, by Disease Indications USD Million (2025-2030)
  • Table 214. Australia Childhood Vaccines, by Type USD Million (2025-2030)
  • Table 215. Australia Childhood Vaccines, by Route of Administration USD Million (2025-2030)
  • Table 216. Australia Childhood Vaccines, by Technology USD Million (2025-2030)
  • Table 217. Australia Childhood Vaccines, by Disease Indications USD Million (2025-2030)
  • Table 218. Rest of Asia-Pacific Childhood Vaccines, by Type USD Million (2025-2030)
  • Table 219. Rest of Asia-Pacific Childhood Vaccines, by Route of Administration USD Million (2025-2030)
  • Table 220. Rest of Asia-Pacific Childhood Vaccines, by Technology USD Million (2025-2030)
  • Table 221. Rest of Asia-Pacific Childhood Vaccines, by Disease Indications USD Million (2025-2030)
  • Table 222. Europe Childhood Vaccines, by Country USD Million (2025-2030)
  • Table 223. Europe Childhood Vaccines, by Type USD Million (2025-2030)
  • Table 224. Europe Childhood Vaccines, by Route of Administration USD Million (2025-2030)
  • Table 225. Europe Childhood Vaccines, by Technology USD Million (2025-2030)
  • Table 226. Europe Childhood Vaccines, by Disease Indications USD Million (2025-2030)
  • Table 227. Germany Childhood Vaccines, by Type USD Million (2025-2030)
  • Table 228. Germany Childhood Vaccines, by Route of Administration USD Million (2025-2030)
  • Table 229. Germany Childhood Vaccines, by Technology USD Million (2025-2030)
  • Table 230. Germany Childhood Vaccines, by Disease Indications USD Million (2025-2030)
  • Table 231. France Childhood Vaccines, by Type USD Million (2025-2030)
  • Table 232. France Childhood Vaccines, by Route of Administration USD Million (2025-2030)
  • Table 233. France Childhood Vaccines, by Technology USD Million (2025-2030)
  • Table 234. France Childhood Vaccines, by Disease Indications USD Million (2025-2030)
  • Table 235. Italy Childhood Vaccines, by Type USD Million (2025-2030)
  • Table 236. Italy Childhood Vaccines, by Route of Administration USD Million (2025-2030)
  • Table 237. Italy Childhood Vaccines, by Technology USD Million (2025-2030)
  • Table 238. Italy Childhood Vaccines, by Disease Indications USD Million (2025-2030)
  • Table 239. United Kingdom Childhood Vaccines, by Type USD Million (2025-2030)
  • Table 240. United Kingdom Childhood Vaccines, by Route of Administration USD Million (2025-2030)
  • Table 241. United Kingdom Childhood Vaccines, by Technology USD Million (2025-2030)
  • Table 242. United Kingdom Childhood Vaccines, by Disease Indications USD Million (2025-2030)
  • Table 243. Netherlands Childhood Vaccines, by Type USD Million (2025-2030)
  • Table 244. Netherlands Childhood Vaccines, by Route of Administration USD Million (2025-2030)
  • Table 245. Netherlands Childhood Vaccines, by Technology USD Million (2025-2030)
  • Table 246. Netherlands Childhood Vaccines, by Disease Indications USD Million (2025-2030)
  • Table 247. Rest of Europe Childhood Vaccines, by Type USD Million (2025-2030)
  • Table 248. Rest of Europe Childhood Vaccines, by Route of Administration USD Million (2025-2030)
  • Table 249. Rest of Europe Childhood Vaccines, by Technology USD Million (2025-2030)
  • Table 250. Rest of Europe Childhood Vaccines, by Disease Indications USD Million (2025-2030)
  • Table 251. MEA Childhood Vaccines, by Country USD Million (2025-2030)
  • Table 252. MEA Childhood Vaccines, by Type USD Million (2025-2030)
  • Table 253. MEA Childhood Vaccines, by Route of Administration USD Million (2025-2030)
  • Table 254. MEA Childhood Vaccines, by Technology USD Million (2025-2030)
  • Table 255. MEA Childhood Vaccines, by Disease Indications USD Million (2025-2030)
  • Table 256. Middle East Childhood Vaccines, by Type USD Million (2025-2030)
  • Table 257. Middle East Childhood Vaccines, by Route of Administration USD Million (2025-2030)
  • Table 258. Middle East Childhood Vaccines, by Technology USD Million (2025-2030)
  • Table 259. Middle East Childhood Vaccines, by Disease Indications USD Million (2025-2030)
  • Table 260. Africa Childhood Vaccines, by Type USD Million (2025-2030)
  • Table 261. Africa Childhood Vaccines, by Route of Administration USD Million (2025-2030)
  • Table 262. Africa Childhood Vaccines, by Technology USD Million (2025-2030)
  • Table 263. Africa Childhood Vaccines, by Disease Indications USD Million (2025-2030)
  • Table 264. North America Childhood Vaccines, by Country USD Million (2025-2030)
  • Table 265. North America Childhood Vaccines, by Type USD Million (2025-2030)
  • Table 266. North America Childhood Vaccines, by Route of Administration USD Million (2025-2030)
  • Table 267. North America Childhood Vaccines, by Technology USD Million (2025-2030)
  • Table 268. North America Childhood Vaccines, by Disease Indications USD Million (2025-2030)
  • Table 269. United States Childhood Vaccines, by Type USD Million (2025-2030)
  • Table 270. United States Childhood Vaccines, by Route of Administration USD Million (2025-2030)
  • Table 271. United States Childhood Vaccines, by Technology USD Million (2025-2030)
  • Table 272. United States Childhood Vaccines, by Disease Indications USD Million (2025-2030)
  • Table 273. Canada Childhood Vaccines, by Type USD Million (2025-2030)
  • Table 274. Canada Childhood Vaccines, by Route of Administration USD Million (2025-2030)
  • Table 275. Canada Childhood Vaccines, by Technology USD Million (2025-2030)
  • Table 276. Canada Childhood Vaccines, by Disease Indications USD Million (2025-2030)
  • Table 277. Mexico Childhood Vaccines, by Type USD Million (2025-2030)
  • Table 278. Mexico Childhood Vaccines, by Route of Administration USD Million (2025-2030)
  • Table 279. Mexico Childhood Vaccines, by Technology USD Million (2025-2030)
  • Table 280. Mexico Childhood Vaccines, by Disease Indications USD Million (2025-2030)
  • Table 281. Research Programs/Design for This Report
  • Table 282. Key Data Information from Secondary Sources
  • Table 283. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Childhood Vaccines: by Type USD Million (2018-2023)
  • Figure 5. Global Childhood Vaccines: by Route of Administration USD Million (2018-2023)
  • Figure 6. Global Childhood Vaccines: by Technology USD Million (2018-2023)
  • Figure 7. Global Childhood Vaccines: by Disease Indications USD Million (2018-2023)
  • Figure 8. South America Childhood Vaccines Share (%), by Country
  • Figure 9. Asia Pacific Childhood Vaccines Share (%), by Country
  • Figure 10. Europe Childhood Vaccines Share (%), by Country
  • Figure 11. MEA Childhood Vaccines Share (%), by Country
  • Figure 12. North America Childhood Vaccines Share (%), by Country
  • Figure 13. Global Childhood Vaccines share by Players 2023 (%)
  • Figure 14. Global Childhood Vaccines share by Players (Top 3) 2023(%)
  • Figure 15. Global Childhood Vaccines share by Players (Top 5) 2023(%)
  • Figure 16. BCG Matrix for key Companies
  • Figure 17. GlaxoSmithKline plc. (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 18. GlaxoSmithKline plc. (United Kingdom) Revenue: by Geography 2023
  • Figure 19. Pfizer, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 20. Pfizer, Inc. (United States) Revenue: by Geography 2023
  • Figure 21. Merck & Co., Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 22. Merck & Co., Inc. (United States) Revenue: by Geography 2023
  • Figure 23. Sanofi Pasteur SA (France) Revenue, Net Income and Gross profit
  • Figure 24. Sanofi Pasteur SA (France) Revenue: by Geography 2023
  • Figure 25. CSL Limited (Australia) Revenue, Net Income and Gross profit
  • Figure 26. CSL Limited (Australia) Revenue: by Geography 2023
  • Figure 27. Emergent Bio Solutions, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 28. Emergent Bio Solutions, Inc. (United States) Revenue: by Geography 2023
  • Figure 29. Johnson & Johnson (United States) Revenue, Net Income and Gross profit
  • Figure 30. Johnson & Johnson (United States) Revenue: by Geography 2023
  • Figure 31. Serum Institute of India (India) Revenue, Net Income and Gross profit
  • Figure 32. Serum Institute of India (India) Revenue: by Geography 2023
  • Figure 33. AstraZeneca (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 34. AstraZeneca (United Kingdom) Revenue: by Geography 2023
  • Figure 35. Bavarian Nordic (Denmark) Revenue, Net Income and Gross profit
  • Figure 36. Bavarian Nordic (Denmark) Revenue: by Geography 2023
  • Figure 37. Global Childhood Vaccines: by Type USD Million (2025-2030)
  • Figure 38. Global Childhood Vaccines: by Route of Administration USD Million (2025-2030)
  • Figure 39. Global Childhood Vaccines: by Technology USD Million (2025-2030)
  • Figure 40. Global Childhood Vaccines: by Disease Indications USD Million (2025-2030)
  • Figure 41. South America Childhood Vaccines Share (%), by Country
  • Figure 42. Asia Pacific Childhood Vaccines Share (%), by Country
  • Figure 43. Europe Childhood Vaccines Share (%), by Country
  • Figure 44. MEA Childhood Vaccines Share (%), by Country
  • Figure 45. North America Childhood Vaccines Share (%), by Country
List of companies from research coverage that are profiled in the study
  • GlaxoSmithKline plc. (United Kingdom)
  • Pfizer, Inc. (United States)
  • Merck & Co., Inc. (United States)
  • Sanofi Pasteur SA (France)
  • CSL Limited (Australia)
  • Emergent Bio Solutions, Inc. (United States)
  • Johnson & Johnson (United States)
  • Serum Institute of India (India)
  • AstraZeneca (United Kingdom)
  • Bavarian Nordic (Denmark)
Additional players considered in the study are as follows:
Mitsubishi Tanabe Pharma Corporation (Japan) , Daiichi Sankyo Company, Limited (Japan)
Select User Access Type

Key Highlights of Report


Jan 2024 227 Pages 67 Tables Base Year: 2023 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Childhood Vaccines Quantitative research analysis
Global Childhood Vaccines Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

The standard version of the report profiles players such as GlaxoSmithKline plc. (United Kingdom), Pfizer, Inc. (United States), Merck & Co., Inc. (United States), Sanofi Pasteur SA (France), CSL Limited (Australia), Emergent Bio Solutions, Inc. (United States), Johnson & Johnson (United States), Serum Institute of India (India), AstraZeneca (United Kingdom) and Bavarian Nordic (Denmark) etc.
The Study can be customized subject to feasibility and data availability. Please connect with our sales representative for further information.
"Increasing Company Initiatives to Enhance Vaccine R&D" is seen as one of major influencing trends for Childhood Vaccines Market during projected period 2023-2030.
The Childhood Vaccines market study includes a random mix of players, including both market leaders and some top growing emerging players. Connect with our sales executive to get a complete company list in our research coverage.

Know More About Global Childhood Vaccines Report?

Have a Query? Click Here

Other Related Reports

Bone Marrow Transplantation Comprehensive Study by Type (Allogeneic Bone Marrow Transplant, Autologous Bone Marrow Transplant), Indication (Leukemia, Lymphoma, Myeloma, Myelodysplasia, Myeloprolifera...
$ 3650
Anti-aging Services Comprehensive Study by Type (Face, Body), Form (Cream, Serum, Gel), Ingredient (Vitamin E, Vitamin C, Retinol, Aloe, Shea Butter, Alpha Hydroxy), Container (Jar, Bottle, Tube, Pu...
$ 3500
Paget's Disease Treatment Comprehensive Study by Route of Administration (Oral, Intravenous, Topical), Treatment (Actonel, Reclast, Zoledronic Acid, Fosamax, Miacalcin, Aredia, Calcitonin, Zometa, Ot...
$ 3750
Acute Lung Injury Comprehensive Study by Therapy (Pharmacotherapy, Mechanical Ventilation, Adjunctive Procedures, Fluid Management, Others), End-users (Hospitals, Clinics, Ambulatory Surgical Centres...
$ 3450
Telmisartan and Hydrochlorothiazide Drug Comprehensive Study by Type (80 mg/12.5 mg tablets, 40 mg/12.5 mg tablets, 80 mg/25 mg tablets), Application (Hypertension, Fluid Retention, Prevents Heart At...
$ 3750
Actinic Keratosis Therapeutics Comprehensive Study by Type (Combination Therapy, Photodynamic Therapy), Application (Hospitals & Oncology Centers, Dermatology Clinics, Ambulatory Surgical Centers), D...
$ 3650